
| Disease Domain | Count |
|---|---|
| Neoplasms | 3 |
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 3 |
Target- |
Mechanism Apoptosis stimulants [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Apoptosis stimulants [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Apoptosis stimulants [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jun 2026 |
Sponsor / Collaborator |
Start Date01 May 2026 |
Sponsor / Collaborator |
Start Date10 Mar 2026 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
Ir(III) complexes L3(Universidad de Burgos) | Neoplasms More | Preclinical |
Ir(III) complexes L2(Universidad de Burgos) | Neoplasms More | Preclinical |
Ir(III) complexes L1(Universidad de Burgos) | Neoplasms More | Preclinical |





